These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. Mestre TA; Fereshtehnejad SM; Berg D; Bohnen NI; Dujardin K; Erro R; Espay AJ; Halliday G; van Hilten JJ; Hu MT; Jeon B; Klein C; Leentjens AFG; Marinus J; Mollenhauer B; Postuma R; Rajalingam R; Rodríguez-Violante M; Simuni T; Surmeier DJ; Weintraub D; McDermott MP; Lawton M; Marras C J Parkinsons Dis; 2021; 11(2):395-404. PubMed ID: 33682731 [TBL] [Abstract][Full Text] [Related]
4. Characterization of Parkinson's Disease Subtypes and Related Attributes. Shakya S; Prevett J; Hu X; Xiao R Front Neurol; 2022; 13():810038. PubMed ID: 35677337 [TBL] [Abstract][Full Text] [Related]
5. Parkinson's Disease Subtyping Using Clinical Features and Biomarkers: Literature Review and Preliminary Study of Subtype Clustering. Lee SH; Park SM; Yeo SS; Kwon O; Lee MK; Yoo H; Ahn EK; Jang JY; Jang JH Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054279 [TBL] [Abstract][Full Text] [Related]
6. Subtypes of Parkinson's Disease: What Do They Tell Us About Disease Progression? Fereshtehnejad SM; Postuma RB Curr Neurol Neurosci Rep; 2017 Apr; 17(4):34. PubMed ID: 28324303 [TBL] [Abstract][Full Text] [Related]
7. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Espay AJ; Schwarzschild MA; Tanner CM; Fernandez HH; Simon DK; Leverenz JB; Merola A; Chen-Plotkin A; Brundin P; Kauffman MA; Erro R; Kieburtz K; Woo D; Macklin EA; Standaert DG; Lang AE Mov Disord; 2017 Mar; 32(3):319-324. PubMed ID: 28233927 [TBL] [Abstract][Full Text] [Related]
8. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K; Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032 [TBL] [Abstract][Full Text] [Related]
9. Progress towards therapies for disease modification in Parkinson's disease. Vijiaratnam N; Simuni T; Bandmann O; Morris HR; Foltynie T Lancet Neurol; 2021 Jul; 20(7):559-572. PubMed ID: 34146514 [TBL] [Abstract][Full Text] [Related]
10. The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease. Bloem BR; Marks WJ; Silva de Lima AL; Kuijf ML; van Laar T; Jacobs BPF; Verbeek MM; Helmich RC; van de Warrenburg BP; Evers LJW; intHout J; van de Zande T; Snyder TM; Kapur R; Meinders MJ BMC Neurol; 2019 Jul; 19(1):160. PubMed ID: 31315608 [TBL] [Abstract][Full Text] [Related]
11. Gender differences in dopaminergic system dysfunction in de novo Parkinson's disease clinical subtypes. Boccalini C; Carli G; Pilotto A; Padovani A; Perani D Neurobiol Dis; 2022 Jun; 167():105668. PubMed ID: 35219854 [TBL] [Abstract][Full Text] [Related]
12. Data-Driven Subtyping of Parkinson's Disease Using Longitudinal Clinical Records: A Cohort Study. Zhang X; Chou J; Liang J; Xiao C; Zhao Y; Sarva H; Henchcliffe C; Wang F Sci Rep; 2019 Jan; 9(1):797. PubMed ID: 30692568 [TBL] [Abstract][Full Text] [Related]
13. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. Lang AE; Espay AJ Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751 [TBL] [Abstract][Full Text] [Related]
14. Advancing Personalized Medicine in Common Forms of Parkinson's Disease through Genetics: Current Therapeutics and the Future of Individualized Management. Reed X; Schumacher-Schuh A; Hu J; Bandres-Ciga S J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33804504 [TBL] [Abstract][Full Text] [Related]
15. Genetically Targeted Clinical Trials in Parkinson's Disease: Learning from the Successes Made in Oncology. Sjögren M; Huttunen HJ; Svenningsson P; Widner H Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680924 [TBL] [Abstract][Full Text] [Related]
16. Precision Medicine in Parkinson's Disease: From Genetic Risk Signals to Personalized Therapy. Straccia G; Colucci F; Eleopra R; Cilia R Brain Sci; 2022 Sep; 12(10):. PubMed ID: 36291241 [TBL] [Abstract][Full Text] [Related]
17. The TRACK-PD study: protocol of a longitudinal ultra-high field imaging study in Parkinson's disease. Wolters AF; Heijmans M; Michielse S; Leentjens AFG; Postma AA; Jansen JFA; Ivanov D; Duits AA; Temel Y; Kuijf ML BMC Neurol; 2020 Aug; 20(1):292. PubMed ID: 32758176 [TBL] [Abstract][Full Text] [Related]
18. The emerging science of precision medicine and pharmacogenomics for Parkinson's disease. Payami H Mov Disord; 2017 Aug; 32(8):1139-1146. PubMed ID: 28686320 [TBL] [Abstract][Full Text] [Related]